New opportunities in treatment of patients with discirculatory encephalopathy: emphasis on nervous growth factor

doi:10.26565/2312-5675-2020-13-11

Tamara S. Mishchenko V. N. Karazin Kharkiv National University, Maidan Svobody, 6, Kharkiv, 61022, Ukraine https://orcid.org/0000-0002-4086-890X
Viktoriya V. Sokolik State institution "The Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Akademika Pavlova st., 61068 https://orcid.org/0000-0001-6829-2300
Vladislav M. Mishchenko State institution "The Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Akademika Pavlova st., 61068 https://orcid.org/0000-0003-0429-8572
Ivan V. Darii State institution "The Institute of Neurology, Psychiatry and Narcology of the National Academy of Medical Sciences of Ukraine", Kharkiv, Akademika Pavlova st., 61068 https://orcid.org/0000-0001-8204-6325

DOI: https://doi.org/10.26565/2312-5675-2020-13-11

Keywords: Memostim® phytocomplex, discirculatory encephalopathy, cognitive impairment, psychoemotional state, neuron growth factor

Abstract

The paper presents the results of research on the role of neuronal growth factors in the development and progression of cognitive and psychoemotional disorders. Peculiarities of Bacopa Monier and Ginkgo Biloba influence on structural and functional changes of the brain in the experiment and in certain groups of patients are shown. The results of treatment with phytocomplex (FC) Memostim® (fixed combination of Bacopa Monier - 150 mg and Ginkgo Biloba - 120 mg) of 30 patients with DE II grade due to atherosclerosis and hypertension are described. The control group consisted of 30 patients with grade II DE who were not prescribed FC Memostim®. After 3 months of treatment with FC Memostim®, a decrease in the frequency and severity of cephalic, vestibulo-atactic and asthenic syndromes was observed in patients. There was a significant improvement in cognitive functions (on the MoSA scale) and psycho-emotional state of patients. There was a significant improvement in the calculated operations and attention (by 22% relative to baseline, p <0.05) and the overall score on the test (+ 8%, p> 0.05). The general tendency to improve visual-constructive functions, memory, speech, executive functions, abstract thinking and orientation has been identified. Similar results of the effect of FC Memostim® on cognitive functions were obtained from the FAB questionnaire. According to the results of the survey of patients on the scale of quality of life, a significant positive dynamics of the integrative index (statistically significant increase by 31%), index of psychological well-being (increase by 32%), self-satisfaction (by 28%), indicators of physical well-being (by 18%) after 3 months of treatment with FC Memostim®. The level of neuronal growth factor (β-NGF) increased statistically significantly (by 67%). The analysis of the obtained data testifies to the effectiveness and safety of FC Memostim® in the treatment of patients with DE. Thus, the obtained data demonstrate the profound effect of FC Memostim® on the symptoms of cognitive and psychoemotional disorders in patients with DE, which is associated with an increase in NGF levels on the background of the course.

Downloads

Download data is not yet available.

References

Valery L Feigin. Anthology of stroke epidemiology in the 20th and 21st centuries: Assessing the past, the present, and envisioning the future. J of Stroke. 2019, vol. 14, no. 3, pp. 223-237.

Mishchenko T.S., Zdesenko I.V., Mishchenko V.N. New opportunities in the treatment of patients with dyscirculatory encephalopathy. International Journal of Neurology. 2015, no. 5(75), pp. 55-64.

Levin O.S. Dyscirculatory encephalopathy: modern ideas about the mechanisms of development and treatment. Consilium medicum. 2007, no. 8, pp. 72–79.

Galluzzi S., Sheu C.-F., Zanetti O. et al. Distinctive clinical features of mild cognitive impairment with subcortical cerebrovascular disease. Dement. Geriatr. Cogn. Disord. 2005, vol. 19, pp. 196–203.

Yakhno N.N., Levin O.S., Damulin I.V. Comparison of clinical and MRI data in discirculatory encephalopathy. Message 2: cognitive impairment. Nevrol. journal. 2001, vol. 6, no 3, pp. 10–19.

Preobrazhenskaya I.S., Yakhno N.N. Vascular cognitive impairment: clinical manifestations, diagnosis, treatment. Nevrol. journal. 2007, vol. 12, no. 5, pp. 45–50.

Lokshina A. B. Zakharov V. V. Mild and moderate cognitive impairment in discirculatory encephalopathy. Nevrol. journal. 2005, vol. 11, no. 1, pp. 57–63.

Gomazkov O.A. Growth and neurotrophic factors in the regulation of stem cell transformation and neurogenesis. Neurochemistry.2007, no. 24, pp. 101–112.

Popova N.K., Morozova M. Neurotrophic factor of the brain: effect on genetically and epigenetically determined behavioral disorders, Sechenov russ. fiziol. journal. 2013, no. 99, pp. 1125–1137.

Weissmiller, A.M., and Wu, С. Current advances in using neurotrophic factors to treat neurodegenerative disorders, Transl. Neurodegener. 2012, no. 14. DOI: 10.1186/2047 9158 1–14.

Homberg, J.R., Molteni, R., Calabrese, F., Riva, M.A. The serotonin BDNF duo: developmental implications for the vulnerability to psychopathology, Neurosci. Biobehav. Rev.2014, no. 43, pp. 35–47.

Lejri I. et al. Ginkgo biloba extract increases neurite outgrowth and activates the Akt/mTOR pathway. PLoS One. 2019, vol. 14, no. 12: e0225761.

Xu S.L. Isorhamnetin, A Flavonol Aglycone from Ginkgo biloba L., Induces Neuronal Differentiation of Cultured PC12 Cells: Potentiating the Effect of Nerve Growth Factor. Evid Based Complement Alternat Med. 2012, vol. 2012: 278273.

Priyanka H.P. Bacopa monnieri and L-deprenyl differentially enhance the activities of antioxidant enzymes and the expression of tyrosine hydroxylase and nerve growth factor via ERK 1/2 and NF-κB pathways in the spleen of female wistar rats. Neurochem Res. 2013, vol. 38, no. 1, pp. 141-152.

Zakharov V.V., Bakulin I.S. Bilobil Intens - a neuroprotective drug of plant origin: a range of applications in neurology. Journal of Nervous Diseases. 2017, no. 1, pp. 15-20.

Mishchenko T.S., Mishchenko V.N., Lapshina I.A. The use of ginkgo biloba extract in the treatment of patients with chronic vascular diseases of the brain. International Neurological Journal. 2015, no. 5 (75), pp. 130-134.

Steven T., Dekosky, Jeff D. Williamson et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008, no. 300(19), pp.2253-2262.

Weinmann S., Roll S., Schwarzbach C., et al. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC geriatrics. 2010, no. 10, article 14. DOI: 10.1186/1471-2318-10-14.

Le X.T., Nguyet Pham H.T. et al. Protective eff ects of Bacopa monnieri on ischemia-induced cognitive defi cits in mice: the possible contribution of bacopaside I and underlying mechanism. J. Ethnopharmacol. 2015, pp. 37-45.

Sudharani, D., Krishna K. L.; Deval K. et al. Pharmacological profiles of Bacopa monnieri: a review. Int. J. Pharm. 2011, no. 1(1), pp. 15–23.

Koilmani Emmanuvel Rajan et al. Molecular and Functional Characterization of Bacopa monniera: A Retrospective Review. Evid Based Complement Alternat Med. 2015. DOI: 10.1155/2015/945217.

Ramesh Kumar R. et al. Bacopa monniera a Potent Neuroprotector Against Transient Global Cerebral Ischemia Induced Hippocampal Damage and Memory Function. International Journal of Anatomical Sciences. 2012, no. 3(2), pp. 26-32.

Yellamma Kuna et al. Neuroprotective effect of Bacopa monniera on memory deficits and ATPase system in Alzheimer’s disease (AD) induced mice. Journal of Scientific and Innovative Research. 2013, no. 2(4), pp. 719-735.

Sebastian Aguiar et al. Neuropharmacological Review of the Nootropic Herb Bacopa monnieri. Rejuvenation Res. 2013, no. 16(4), pp. 313–326. DOI: 10.1089/rej.2013.1431.

C. Ramachandran, K.W. Quirin, E. Escalon [et al.]. Improved Neuroprotective Effects by Combining Bacopa monnieri and Rosmarinus officinalis Supercritical CO2 Extracts. J Evid Based Complementary Altern Med. 2014, vol. 19, no. 2, pp. 119-127.

Priyanka H., Bala P. Bacopa Monnieri and L-Deprenyl Differentially Enhance the Activity of Antioxidant Enzymes and Expression of Tyrosine Hydroxylase and Nerve Growth Factor via ERK 1/2 and NFκB Pathways in the Spleen of Female Wistar Rats. Neurochem Res. 2013, vol. 38, pp. 141-152.

Pandareesh M. et al. Cognition Enhancing and Neuromodulatory Propensity of Bacopa Monniera Extract against Scopolamine Induced Cognitive Impairments in Rat Hippocampus. Neurochem Res. 2016, no. 5, pp. 985–999.

Kumar S. et al. Neuroprotective, Neurotrophic and Anti-Oxidative Role of Bacopa monnieri on CUS Induced Model of Depression in Rat. Neurochem Res. 2016, no. 11, pp. 3083–3094.

Bilgiç A. et al. Exploring the association between depression, suicidality and serum neurotrophin levels in adolescents. Int J Psychiatry Clin Pract. 2020, vol 6, pp. 1-8.

Ciafrè S. et al. Nerve growth factor in the psychiatric brain. Riv Psichiatr. 2020, vol. 55, no. 1, pp. 4-15.

Aguiar S., Borowski T. Neuropharmacological Review of the Nootropic Herb Bacopa monnieri. Rejuventation Research. 2013, vol. 6 no. 4, pp. 313-326

Chaudhari K. et al. Neurocognitive Effect of Nootropic Drug Brahmi (Bacopa monnieri) in Alzheimer’s Disease. Annals of Neuroscience. 2017, vol. 24, pp. 111-122

Kongkeaw Ch. et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology. 2014, no. 1, pp. 528–535. DOI: 10.1016/j.jep.2013.11.008.

Kean J. et al. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complementary Therapies in Medicine. 2016, vol. 29, pp. 56-62.